A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients
Tetsuo Tani(Keio University), Kenzo Soejima(Keio University), Shinnosuke Ikemura(Keio University), Keiko Ohgino(Keio University), Satoshi Yoda(Harvard University), Hideki Terai(Kitasato Institute Hospital), Kota Ishioka(Keio University), Daisuke Arai(Keio University), Hiroyuki Yasuda(Beth Israel Deaconess Medical Center), Katsuhiko Naoki(Broad Institute), Ryosuke Satomi(Tokyo Medical Center), Takashi Sato(Kitasato University), Sohei Nakayama(Beth Israel Deaconess Medical Center)
Cited by 1
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565
Activating Mutations of the Noonan Syndrome-Associated <b> <i>SHP2/PTPN11</i> </b> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia
|Cancer Research|2004|512
<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
|Oncotarget|2015|159
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in <i>ROS1</i> Fusion–Positive Lung Cancer
|Clinical Cancer Research|2021|137